Primary source: Cancellation of Notified Cosmetic Products
The NPRA has formally notified stakeholders about identified non-compliance issues in the release of plasma product lots, impacting compliance workflows.
Non-compliance in the lot release process can significantly affect product safety, compliance, and market access, thus necessitating immediate corrective action.
Entities affected by this notification must review their plasma product lot processes and ensure compliance with NPRA regulations. Affected stakeholders should adjust workflows to address non-compliance issues.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Entities affected by this notification must review their plasma product lot processes and ensure compliance with NPRA regulations. Affected stakeholders should adjust workflows to address non-compliance issues.
The National Pharmaceutical Regulatory Agency (NPRA) of Malaysia has issued a notification regarding non-compliance associated with the lot release of plasma products. This formal communication underlines the necessity for stakeholders to adhere to regulatory requirements to ensure public safety.
What changed: The NPRA has formally notified stakeholders about identified non-compliance issues in the release of plasma product lots, impacting compliance workflows.
Why it matters: Non-compliance in the lot release process can significantly affect product safety, compliance, and market access, thus necessitating immediate corrective action.
Practical implication: Entities affected by this notification must review their plasma product lot processes and ensure compliance with NPRA regulations. Affected stakeholders should adjust workflows to address non-compliance issues.
Published from the regulator source ingestion pipeline after PV impact triage.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
